Head-to-head · free
Oric Pharmaceuticals vs Insulet Corp.
ORIC vs PODD — return on capital, cash generation, margins and balance sheet side by side.
ORIC
1 / 4
measures where ORIC leads
PODD
3 / 4
measures where PODD leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ORIC · FY2025 | PODD · FY2025 |
|---|---|---|
| Revenue | — | $2.7B |
| Net income | (129.5M) | $247.1M |
| Revenue growth (yearly, multi-year) | — | 25.3% |
| Free cash flow | (111.7M) | $377.7M |
| Free cash flow margin | — | 13.9% |
| Net cash / (debt) | — | — |
| ROIC | — | 13.6% |
| Return on equity | -41.3% | 18.1% |
| Gross margin | — | 71.6% |
| Operating margin | — | 17.5% |
| Net debt / EBITDA | 0.32x | 0.41x |
Figures are as reported by each company; latest fiscal year shown.
Where Oric Pharmaceuticals's cash went (FY2025)
- Capital spending
- $712000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Insulet Corp.'s cash went (FY2025)
- Capital spending
- $191.6M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free